CN114317345A - Preparation method of lactococcus lactis GEM particles - Google Patents
Preparation method of lactococcus lactis GEM particles Download PDFInfo
- Publication number
- CN114317345A CN114317345A CN202111627882.0A CN202111627882A CN114317345A CN 114317345 A CN114317345 A CN 114317345A CN 202111627882 A CN202111627882 A CN 202111627882A CN 114317345 A CN114317345 A CN 114317345A
- Authority
- CN
- China
- Prior art keywords
- lactococcus lactis
- gem particles
- gem
- particles
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002245 particle Substances 0.000 title claims abstract description 58
- 241000194035 Lactococcus lactis Species 0.000 title claims abstract description 30
- 235000014897 Streptococcus lactis Nutrition 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 239000006228 supernatant Substances 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 13
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- 241000894006 Bacteria Species 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 9
- 238000009835 boiling Methods 0.000 claims description 6
- 230000001580 bacterial effect Effects 0.000 claims description 5
- 238000005119 centrifugation Methods 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 241000194036 Lactococcus Species 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 2
- 239000012535 impurity Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 6
- 238000006243 chemical reaction Methods 0.000 abstract description 2
- 238000011081 inoculation Methods 0.000 abstract description 2
- 238000009776 industrial production Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 24
- 102000004169 proteins and genes Human genes 0.000 description 24
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 238000004873 anchoring Methods 0.000 description 5
- 238000010494 dissociation reaction Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 229960005486 vaccine Drugs 0.000 description 5
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- 230000005593 dissociations Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 3
- 239000007863 gel particle Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 229940031626 subunit vaccine Drugs 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 239000000568 immunological adjuvant Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 210000002955 secretory cell Anatomy 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000013595 supernatant sample Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N 1-butanol Substances CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 1
- 108010042365 Virus-Like Particle Vaccines Proteins 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001571 immunoadjuvant effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
Images
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The invention discloses a preparation method of lactococcus lactis GEM particles, and belongs to the technical field of preparation of GEM particles. By selecting and controlling parameters such as the culture conditions of strains such as the extracting solution, the reaction conditions, the inoculation ratio and the like, the finally obtained GEM particles have high acquisition rate and strong activity, and lay the foundation for the industrial production of the GEM particles.
Description
Technical Field
The invention belongs to the technical field of preparation of GEM particles, and particularly relates to a preparation method of lactococcus lactis GEM particles.
Background
A Gram-positive enhanced matrix (GEM) surface display system is a novel lactic acid bacteria surface display technology developed by Bosma et al in 2006 and based on the non-activity and non-genetic modification of bacteria-like particles, and is characterized in that the food-grade lactic acid bacteria are subjected to post-treatment in modes of acidification, boiling and the like, so that the obtained hollow particles are obtained, the intracellular and extracellular macromolecular substances such as original Protein, nucleic acid, teichoic acid and the like are removed, and only cell wall peptidoglycan frameworks are left, and the hollow particles are combined with anchoring Protein (PA) formed by a lactococcus lactis AcmA-repeated anchoring hook region to form a novel microorganism surface display technology. Since the technology is discovered, the technology is widely researched in the aspects of vaccine development, adjuvant development, protein purification and the like, shows a huge application prospect, and is expected to become the most promising form of genetic engineering subunit vaccine together with virus-like particle vaccine particularly on the research of mucosal immune vaccine.
Researches show that compared with lactococcus lactis, the GEM particles have the characteristics of small side effect after immunization, high safety and the like because substances such as bacterial nucleic acid, lipoteichoic acid on the surface and the like are removed. Meanwhile, researches find that GEM particles are a natural immunologic adjuvant, can be identified by TLR2, can activate the innate immunity of organisms, can stimulate immune cells to secrete a large amount of cytokines and chemokines to induce inflammatory response, and can enhance the response of an immune system. GEM has an autoimmune adjuvant effect. Saluja et al showed that the use of GEM particles as an immunoadjuvant greatly reduced the amount of HA antigen, significantly enhanced the systemic immune response, and the particles also shifted the immune response pattern from Th2 to balanced Th1/Th2, enhancing the protective efficacy of influenza subunit vaccines. The result of Karina Ramirez and the like in researching the plague subunit vaccine by utilizing the GEM technology is consistent with the research result of V.Saluja and the like, and the change of CD4+ and CD8+ T cells in a mouse body after immunization is found, so that GEM particles can stimulate and promote the maturation of DCs, the number of IFN-gamma secretory cells is increased, the number of IL-4 secretory cells is reduced, the immune response type is shifted to balanced Th1/Th2, and the body is effectively protected. In addition, the GEM particles have good acid resistance, can break through the gastric acid barrier of an organism, and improve the application of mucosal immunity in animal vaccines. In short, the GEM particles as an antigen carrier are a surface display system with strong potential, have good universality and have wide prospects in vaccine development, especially in the application aspect of vaccines developed aiming at a mucous membrane immune system.
However, the GEM particles obtained by the existing preparation method of the GEM particles have the problems of low yield, poor activity and the like, so how to provide a preparation method of the lactococcus lactis GEM particles is a problem to be solved in the field.
Disclosure of Invention
The invention discloses a preparation method of lactococcus lactis GEM particles.
In order to achieve the purpose, the invention adopts the following technical scheme:
a preparation method of lactococcus lactis GEM particles comprises the following steps:
dissolving 5 parts by volume of lactococcus lactis bacterial solution in 1 part by volume of 1.25% -0.625% trichloroacetic acid solution, carrying out boiling water bath for 30min-1h, cooling, and removing impurities to obtain GEM particles;
preferably, the boiling water bath is 30 min;
the acid lactococcus liquid OD600＝0.8-1.2；
Preferably, the acid lactococcus liquid OD600＝1；
Preferably, the trichloroacetic acid is 1.25%;
preferably, the preparation method of the lactococcus lactis liquid comprises the following steps: transferring lactococcus lactis into GM17 liquid according to the proportion of 1:50-1:200, and culturing until OD600 is 1;
preferably, the ratio of lactococcus lactis is 1: 100;
preferably, the culture conditions are 28-32 ℃, 150-;
preferably, the culture conditions are 30 ℃, 180 rpm;
preferably, the bacteria collection method is 2-8 ℃;
preferably, the bacteria collection method is 4 ℃ bacteria collection;
preferably, the 4 ℃ bacteria collection step is centrifugation at 2-8 ℃ and 4000-;
preferably, the 4 ℃ bacteria collection step is centrifugation at 5000rpm at 4 ℃ for 10 min;
preferably, the method comprises the steps of centrifuging at 8000rpm and 4000-;
preferably, the method is to centrifuge at 5000rpm for 15min at 4 ℃, discard the supernatant, resuspend the pellet with PBS, wash it twice with PBS, and finally resuspend the PBS to obtain GEM particles.
In conclusion, the invention discloses a preparation method of lactococcus lactis GEM particles. Through selection and control of parameters such as extracting solution, reaction conditions, inoculation ratio and the like, the low-concentration trichloroacetic acid (0.038M, 0.075M) is used for preparing lactococcus lactis GEM particles, the yield is high and can reach 99.99%, the GEM particles prepared by the low-concentration trichloroacetic acid have high anchoring protein binding rate of 7 multiplied by 109The GEM particles can bind 4mg/mL of dockerin, equivalent to 2.5 x 109Individual GEM particles bound 142.85ug PA-anchored protein.
Drawings
FIG. 1 shows the protein removal from GEM particles under the action of acids of different concentrations; a: trichloroacetic acid, B: hydrochloric acid, C: sulfuric acid, D: acetic acid; 1: lactococcus lactis which has not been acid-treated; 2: 10% concentration; 3: 5% concentration; 4: 2.5% concentration; 5: 1.25% concentration; 6: 0.625% concentration;
FIG. 2 is a transmission electron microscope morphology observation of GEM particles; a: GEM particles extracted with 1.25% trichloroacetic acid, B: lactococcus lactis;
FIG. 3 shows the binding condition of GEM particles and PA protein extracted by trichloroacetic acid with different concentrations; m: marker, 1-5: for the combined supernatant samples, the TCA concentration was 0.625%, 1.25%, 2.5%, 5%, 10%, 6-10: for the dissociated supernatant samples, the TCA concentration was 0.625%, 1.25%, 2.5%, 5%, 10%, 11-15: in order to precipitate the sample after dissociation, the concentration of TCA is 0.625%, 1.25%, 2.5%, 5%, 10% in sequence;
FIG. 4 shows the binding of 1.25% trichloroacetic acid-extracted GEM particles with PA proteins of different concentrations; 1: combined supernatant, 2: precipitation after binding, 3: post-dissociation supernatant, 4: precipitating after dissociation; a: PA protein concentration 1.6mg/mL, B: PA protein concentration 2.4mg/mL, C: PA protein concentration 3.2mg/mL, D: the concentration of PA protein was 4.0 mg/mL.
Detailed Description
The technical solutions in the embodiments of the present invention are clearly and completely described below, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1
Extraction of GEM particles
Culture of lactococcus lactis MG1363
After the overnight culture of MG1363 in the medium was confirmed to be correct by gram-stained microscopy and PCR, the medium was transferred to GM17 at a ratio of 1:100 and cultured at 30 ℃ and 180rpm until OD600 was 1. 1mL of the bacterial solution was taken into a 1.5mLEP tube, diluted 10-fold and counted. And (5) remaining bacteria liquid for later use.
Preparation of GEM particles
4 acids of sulfuric acid, hydrochloric acid, acetic acid and trichloroacetic acid are respectively selected for extracting GEM particles, and the concentration of each acid is as follows from high to low: 10.0%, 5.0%, 2.5%, 1.25% and 0.625%.
The specific operation is as follows: respectively taking 10mL of bacterial liquid, and centrifuging at 4 ℃ and 5000rpm for 10 min; the supernatant was discarded, and the cells were washed with an appropriate amount of PBS 2 times and then resuspended in 2mL of an acid of the corresponding concentration. Sealing, heating in boiling water for 30min, and taking out. When the temperature of the sample is returned to room temperature, the sample is centrifuged at 5000rpm at 4 ℃ for 15 min. The supernatant was discarded and the pellet resuspended in a fresh 1.5mL EP tube with the appropriate amount of PBS. After washing with PBS for 2 times, resuspending with 1mL PBS to obtain the prepared GEM particles.
Example 2
Evaluation of GEM particle extraction Effect
Determination of efficiency of GEM particle preparation
100uL of the GEM granule sample prepared after the acid with different concentrations acts on the gel particles are respectively taken out and diluted by 10 times to 10-7And coating the board. The gel particles were cultured overnight at 30 ℃ and then taken out, and the number of viable cells was counted to determine the efficiency of producing the gel particles, and the results are shown in Table 1.
TABLE 1 efficiency of GEM granule preparation under the action of different concentrations of acid
Detection of GEM granule protein removal efficiency
As shown in fig. 1, at 10%, 5%, 2.5%, 1.25% and 0.625% acetic acid, trichloroacetic acid was effective at removing protein at 1.25% and 0.625%; hydrochloric acid and sulfuric acid have poor removal effects.
Morphology Observation of GEM particles
According to the results, GEM particles prepared under the optimal conditions are selected for centrifugation, after centrifugation at 4000rpm for 5min, the supernatant is discarded, 1mL of 2.5% glutaraldehyde fixing solution is added, and fixation is carried out at room temperature for 2-3 h. PBS rinse 3 times, 10min each time. Then dehydrating with 30.0%, 50.0%, 70.0%, 90.0%, 95.0% for 1 time, 20min each time, and then dehydrating with anhydrous ethanol for 2 times, 20min each time; and then using absolute ethyl alcohol: the tert-butanol solution 1:1 and tert-butanol solution are dehydrated for 1 time, 10min each time. Centrifuging at 4000rpm for 5min, removing the supernatant, transferring the dehydrated sample to a sterile vial, freezing at-80 deg.C overnight, taking out the sample to a freeze dryer the next day, drying for 2h, and observing and photographing by a transmission electron microscope. Lactococcus lactis was used as a control without acid treatment.
As shown in fig. 2, GEM particles extracted with 1.25% trichloroacetic acid were morphologically similar to untreated lactococcus lactis.
Determination of the binding efficiency of GEM particles to anchoring proteins
And respectively incubating 100uL of prepared GEM particles with 100uL of different-concentration anchoring proteins, acting at room temperature for 30min, and centrifuging at 5000rpm for 10 min. The supernatant was carefully aspirated and transferred to a new 1.5ml lep tube, protein concentration was determined by BCA method, and protein status in the supernatant was checked by SDS-PAGE. After washing the pellet 2 times with PBS, it was resuspended in 200uL ddH2O, 100uL of which was used for SDS-PAGE to observe GEM-PA binding. After the remaining 100uL of sample is centrifuged at 5000rpm for 10min, the sample is resuspended in 1% SDS solution, and after the sample is heated in boiling water for 10min, the supernatant and the precipitate are respectively taken out for protein detection to observe the GEM-PA dissociation condition.
As shown in fig. 3, after incubation of different concentrations of trichloroacetic acid-extracted GEM particles with PA protein, no PA protein was seen in the supernatant, indicating that PA protein bound to GEM particles; by dissociating the bound GEM-PA particles, the presence of PA protein was clearly seen in the supernatant after dissociation, confirming that GEM particles can bind to PA protein.
As shown in fig. 4D, 1.25% trichloroacetic acid was able to fully bind 400ug PA protein after co-incubation with different concentrations of PA protein, with no PA band seen in the binding supernatant.
The embodiments in the present description are described in a progressive manner, each embodiment focuses on differences from other embodiments, and the same and similar parts among the embodiments are referred to each other.
The previous description of the disclosed embodiments is provided to enable any person skilled in the art to make or use the present invention. Various modifications to the above-described embodiments will be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other embodiments without departing from the spirit or scope of the invention. Thus, the present invention is not intended to be limited to the embodiments shown herein but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.
Claims (7)
1. A preparation method of lactococcus lactis GEM particles is characterized by comprising the following steps:
dissolving 5 parts by volume of lactococcus lactis bacterial solution in 1 part by volume of 1.25% -0.625% trichloroacetic acid solution, carrying out boiling water bath for 30min-1h, cooling, and removing impurities to obtain GEM particles;
the acid lactococcus liquid OD600＝0.8-1.2。
2. The method for producing lactococcus lactis GEM particles according to claim 1, wherein the trichloroacetic acid is 1.25%.
3. The method for preparing lactococcus lactis GEM particles according to claim 1, wherein the method for preparing the lactococcus lactis liquid comprises: lactococcus lactis was transferred to GM17 liquid at a ratio of 1:50 to 1:200, and cultured until OD600 became 1.
4. The method for preparing lactococcus lactis GEM particles as claimed in claim 3, wherein the culture conditions are 28-32 ℃ and 150-200 rpm.
5. The method for producing lactococcus lactis GEM particles according to claim 1, wherein the bacteria collection method is 2-8 ℃.
6. The method for preparing lactococcus lactis GEM particles as claimed in claim 5, wherein the step of collecting the bacteria at 4 ℃ is centrifugation at 8000rpm at 2-8 ℃ for 10min, and the supernatant is discarded, and the cells are washed with PBS for 2 times.
7. The method for preparing lactococcus lactis GEM particles as claimed in claim 1, wherein the method comprises centrifuging at 2-8 ℃ and 4000-.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111627882.0A CN114317345B (en) | 2021-12-28 | 2021-12-28 | Preparation method of lactococcus lactis GEM particles |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111627882.0A CN114317345B (en) | 2021-12-28 | 2021-12-28 | Preparation method of lactococcus lactis GEM particles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114317345A true CN114317345A (en) | 2022-04-12 |
| CN114317345B CN114317345B (en) | 2023-12-01 |
Family
ID=81014778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111627882.0A Active CN114317345B (en) | 2021-12-28 | 2021-12-28 | Preparation method of lactococcus lactis GEM particles |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114317345B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011040811A1 (en) * | 2009-10-02 | 2011-04-07 | Mucosis B.V. | Adjuvanted vaccine formulations |
| CN103103205A (en) * | 2013-03-01 | 2013-05-15 | 江苏省农业科学院 | Gene for encoding recombinant porcine circovirus type 2 (PCV2) Cap protein and application of gene |
| CN109180818A (en) * | 2018-08-08 | 2019-01-11 | 天津大学 | A method of inclusion body is purified using GEM |
| CN110777138A (en) * | 2019-09-10 | 2020-02-11 | 天津大学 | Method for removing recombinant protein endotoxin by using GEM |
| CN112353822A (en) * | 2020-11-18 | 2021-02-12 | 中国药科大学 | Application of lactococcus lactis particles and probiotics in preparation of helicobacter pylori infection resisting medicine |
-
2021
- 2021-12-28 CN CN202111627882.0A patent/CN114317345B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011040811A1 (en) * | 2009-10-02 | 2011-04-07 | Mucosis B.V. | Adjuvanted vaccine formulations |
| CN103103205A (en) * | 2013-03-01 | 2013-05-15 | 江苏省农业科学院 | Gene for encoding recombinant porcine circovirus type 2 (PCV2) Cap protein and application of gene |
| CN109180818A (en) * | 2018-08-08 | 2019-01-11 | 天津大学 | A method of inclusion body is purified using GEM |
| CN110777138A (en) * | 2019-09-10 | 2020-02-11 | 天津大学 | Method for removing recombinant protein endotoxin by using GEM |
| CN112353822A (en) * | 2020-11-18 | 2021-02-12 | 中国药科大学 | Application of lactococcus lactis particles and probiotics in preparation of helicobacter pylori infection resisting medicine |
Non-Patent Citations (1)
| Title |
|---|
| 李鹏成等: ""不同稀酸制备革兰氏阳性增强基质(GEM)颗粒的比较"", 《江苏农业学报》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114317345B (en) | 2023-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104524564B (en) | A kind of crucian Simplex Virus combination vaccine preparation and preparation method and application | |
| CN109680026B (en) | Purification of recombinant CA16 virus-like particles, application of recombinant CA16 virus-like particles in vaccine and vaccine | |
| CN103255163A (en) | EV71virus-like particles as well as preparation method and application thereof | |
| CN104593388B (en) | Crucian herpesvirus disease JDORF25 vaccine as well as preparation method and application thereof | |
| CN103555754B (en) | A kind of lactobacterium casei bacterium shadow and its preparation method and application | |
| CN104593397A (en) | Optimized enterotoxigenic escherichia coli-producing polyvalent antigen gene sequence and application thereof in preventing weaned piglet diarrhea | |
| CN112695053B (en) | Preparation method of recombinant cat interferon | |
| CN111304115A (en) | Lactobacillus casei capable of highly producing 3 forms of organic selenium and application thereof | |
| CN110951814B (en) | Method for preparing prostaglandin E1 by using genetically engineered cyclooxygenase-1 and genetically engineered prostaglandin E synthetase-1 | |
| WO2012155751A1 (en) | A method for preparing hbv vaccine comprising aluminum adjuvant | |
| KR20170118536A (en) | Method for preparing Gram positive bacteria ghosts by the treatment with hydrochloric acid | |
| CN111420037A (en) | Application of phage lyase L ysep3 in preparation of broad-spectrum antibacterial drugs | |
| CN114317345A (en) | Preparation method of lactococcus lactis GEM particles | |
| CN103614387B (en) | The carrying Cap gene of porcine circovirus type 2 gene optimized and recombinant plasmid and application | |
| CN106811428A (en) | It is a kind of to extract the method that membrane vesicle is arranged outside bacterium | |
| CN108285885A (en) | A kind of comma bacillus bacterium shadow preparation method and its application in poultry vaccine | |
| CN114540393B (en) | Porcine circovirus 3-type virus-like particle, construction method and application thereof | |
| CN107488237A (en) | A kind of easy low endotoxin Acinetobacter bauamnnii capsular polysaccharide extracting method | |
| CN104524565B (en) | A kind of new Der p1 nano vaccines for the treatment of lung cancer and its production and use | |
| CN115725634A (en) | Expression cassette of leghemoglobin, expression vector containing leghemoglobin, genetically engineered bacterium and application of leghemoglobin | |
| CN111518222A (en) | Bovine rotavirus fusion protein and calf diarrhea multi-vaccine | |
| CN111378710B (en) | Industrial production method of recombinant spider silk protein | |
| CN103667334B (en) | Brucella melitensis recombinant bacterial strain M5-Δ bp26-Δ znuA and preparation method and application | |
| CN108220217B (en) | Attenuated listeria monocytogenes for delivering and expressing exogenous antigen and application thereof | |
| CN117844643B (en) | Preparation method of recombinant influenza vaccine prepared based on transgenic chlorella |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |